Catalyst Event
RemeGen Co Ltd (9995) · Other
From Akros SCHK HK-US Tech 100 Index (ASHUSTC)
3/23/2026, 12:00:00 AM
Announced that its antibody-drug conjugate (ADC) Disitamab Vedotin was approved by China's NMPA for its 4th indication: treatment of HER2-low expressing breast cancer with liver metastases; Medium importance reflects the positive regulatory milestone likely to cause >5% price impact.
Korean Translation
항체-약물 접합체(ADC) 디시타맙 베도틴이 중국 NMPA로부터 4번째 적응증인 HER2 저발현 간 전이성 유방암 치료제로 승인받음. 주요 규제 승인으로 5% 이상의 주가 영향이 예상됨.
Related Recent Events
SALESFORCE INC (CRM) · Earnings Release
Salesforce's Q1 FY2027 earnings release is scheduled.
5/27/2026, 12:00:00 AM
Lenovo Group Ltd (992) · Earnings Release
Lenovo Group is scheduled to release its fourth-quarter and full-year financial results for the fiscal year 2025/2026. Price impact is estimated at ≥10% due to the significance of annual results and guidance, scheduled.
5/21/2026, 12:00:00 AM
NVIDIA Corporation (NVDA) · Earnings Release
NVIDIA's Q1 Fiscal Year 2027 earnings report is scheduled for May 20, 2026; earnings releases for major tech companies are expected to result in price movements exceeding 10% and are scheduled.
5/20/2026, 12:00:00 AM
AppLovin Corporation (APP) · Earnings Release
AppLovin's Q1 2026 earnings release is scheduled for May 13, 2026. Based on historical data where earnings results often lead to price swings over 5%, a significant market reaction is expected.
5/13/2026, 12:00:00 AM
Arista Networks Inc (ANET) · Earnings Release
Arista Networks is scheduled to release its Q1 2026 financial results with company revenue of $2.6 billion forecasted; a medium impact is estimated due to typical earnings volatility, scheduled.
5/4/2026, 12:00:00 AM
Shopify Inc (SHOP) · Earnings Release
Q1 2026 earnings release is scheduled for April 30, 2026, with revenue guidance of approximately $3.1 billion; low impact estimated as it is a routine scheduling announcement scheduled.
4/30/2026, 12:00:00 AM